Summit Therapeutics
SMMT
166 hedge funds and large institutions have $1.85B invested in Summit Therapeutics in 2024 Q3 according to their latest regulatory filings, with 64 funds opening new positions, 52 increasing their positions, 34 reducing their positions, and 18 closing their positions.
256% more first-time investments, than exits
New positions opened: 64 | Existing positions closed: 18
228% more capital invested
Capital invested by funds: $563M → $1.85B (+$1.29B)
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
53% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 34
35% more funds holding
Funds holding: 123 → 166 (+43)
1.38% more ownership
Funds ownership: 10.28% → 11.66% (+1.4%)
26% less call options, than puts
Call options by funds: $55.9M | Put options by funds: $75.5M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$47.5M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$29.8M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
+$16.8M |
| 4 |
Aberdeen Group
Edinburgh,
United Kingdom
|
+$15.9M |
| 5 |
DGM
Darwin Global Management
St. Helier,
Jersey
|
+$15.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$10.1M |
| 2 |
State Street
Boston,
Massachusetts
|
-$9.15M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
-$8.1M |
| 4 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$7.35M |
| 5 |
First Trust Advisors
Wheaton,
Illinois
|
-$5.11M |
SMMT Hedge Fund Activity: Q3 2024 in Review
166 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Summit Therapeutics (SMMT) for Q3 2024, worth a combined $1.85B — up 228% from $563M a quarter earlier.
Buyers outnumbered sellers: 64 funds opened new SMMT positions and 18 closed out — a net gain of 46 holders — while 52 added to existing stakes and 34 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $47.5M. The largest seller was Millennium Management, cutting an estimated $10.1M.
- 166 institutional investors held Summit Therapeutics (SMMT) as of Q3 2024, up from 123 in Q2 2024.
- Funds reported $1.85B of Summit Therapeutics stock for Q3 2024, up 228% quarter-over-quarter.
- 64 funds opened new Summit Therapeutics positions in Q3 2024 and 18 closed out, a net change of +46 holders.
- The largest Summit Therapeutics buyer in Q3 2024 was T. Rowe Price Associates, an estimated $47.5M added.
- The largest Summit Therapeutics seller in Q3 2024 was Millennium Management, an estimated $10.1M sold.
Based on aggregated 13F filings for Q3 2024.